DUAL II China: Superior HbA1c reductions and weight loss with insulin degludec/liraglutide (IDegLira) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulin

AIM: To assess the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin degludec (degludec) in Chinese people with type 2 diabetes (T2D) treated with basal insulin. MATERIALS AND METHODS: In DUAL II China, a randomized, double‐blinded, multicentre, treat‐to‐target trial, Chi...

Descripción completa

Detalles Bibliográficos
Autores principales: Pei, Yu, Agner, Bue R., Luo, Bin, Dong, Xiaolin, Li, Dongmei, Liu, Jun, Liu, Lei, Liu, Ming, Lu, Yibing, Nishida, Tomoyuki, Xu, Xiangjin, Mu, Yiming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291809/
https://www.ncbi.nlm.nih.gov/pubmed/34387411
http://dx.doi.org/10.1111/dom.14522

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291809/
https://www.ncbi.nlm.nih.gov/pubmed/34387411
http://dx.doi.org/10.1111/dom.14522

Ejemplares similares